Chemokines and graft-versus-host disease - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 419

[104] Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, Murphy WJ. Combined admin-
istration of antibodies to human interleukin 8 and epidermal growth factor receptor
results in increased antimetastatic effects on human breast carcinoma xenografts. Clin
Cancer Res 2002;8:2655-65.
[105] Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors
is correlated with acute graft-versus-host disease after allogeneic stem cell transplanta-
tion. Biol Blood Marrow Transplant 2005;11:280-7.
[106] Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M, et al. CCL8 is
a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood
2008;111:4403-12.
[107] Ota A, Yamamoto M, Hori T, Miyai S, Naishiro Y, Sohma H, et al. Upregulation of plasma
CCL8 in mouse model of graft-vs-host disease. Exp Hematol 2009;37:525-31.
[108] Loeffler J, Ok M, Morton OC, Mezger M, Einsele H. Genetic polymorphisms in the
cytokine and chemokine system: their possible importance in allogeneic stem cell
transplantation. Curr Top Microbiol Immunol 2010;341:83-96.
[109] Sellami MH, Chaabane M, Kaabi H, Torjemane L, Ladeb S, Othmane TB, et al. Evidence
that erythrocyte DARC-positive phenotype can affect the GVHD occurrence after HLA-
identical sibling HSCT. Transplant Immunol 2011;25:148-52.
[110] Hutter G, Neumann M, Nowak D, Klein S, Kluter H, Hofmann WK. The effect of the
CCR5-delta32 deletion on global gene expression considering immune response and
inflammation. J Inflammation (London) 2011;8:29.
[111] Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in
HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1
infection. Cell 1996;86:367-77.
[112] Bogunia-Kubik K, Duda D, Suchnicki K, Lange A. CCR5 deletion mutation and its as-
sociation with the risk of developing acute graft-versus-host disease after allogeneic
hematopoietic stem cell transplantation. Haematologica 2006;91:1628-34.
[113] Ma Q, Gooley TA, Storb RF. CCR5 expression on cells from HLA-matched unre-
lated marrow donors and graft-versus-host disease. Biol Blood Marrow Transplant
2010;16:132-3.
[114] McDermott DH, Conway SE, Wang T, Ricklefs SM, Agovi MA, Porcella SF, et al. Donor
and recipient chemokine receptor CCR5 genotype is associated with survival after bone
marrow transplantation. Blood 115:2311-8.
[115] Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, et al. Blockade
of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med
2012;367(2):135-145. PMID: 22784116.
[116] Kittan NA, Hilderandt GC. The chemokine system: a possible therapeutic target in
acute graft versus host disease. In: Bruserud O, editor. The Chemokine System in Ex-
perimental and Clinical Hematology. Berlin/Heidelberg: Springer-Verlag; 2010.
p. 97-120.
[117] Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat
2009;19:199-221.
[118] Miklos S, Mueller G, Chang Y, Bouazzaoui A, Spacenko E, Schubert TE, et al. Preven-
tive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of
pulmonary and hepatic graft-versus-host disease. Int J Hematol 2009;89:383-97.

424